Hospital News

      Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

      RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck’s KEYTRUDA Met Primary Endpoint of Disease-Free Survival in Certain Patients With Muscle-Invasive Urothelial Carcinoma After Surgery

      Recent Articles